Angion signs licensing option with Memorial Sloan Kettering Cancer Center

According to the company, this novel vaccine platform enables presentation of multiple carbohydrate antigens on a single synthetic scaffold and has been shown to trigger an in vivo immune response to multiple oncology related targets.

The vaccine scaffold can be customized for various clinical indications and represents a major advance for immunotherapy. A Phase I clinical trial is scheduled to start early in 2009, the company said.

Professor Danishefsky is the Kettering chair and director of the laboratory for bioorganic chemistry at the Sloan-Kettering Institute and the centennial professor of chemistry at Columbia University.